Unleashing the power of next generation cancer treatments

View Pipeline

Pipeline

AmMax has built a robust oncology pipeline by leveraging its translational expertise with its lead program, AMB-066, supported by compelling preclinical data and a well-established safety profile across 6 completed clinical trials.

AMB
066 VIEW
AMB
104
AMB
051

Latest News

All News
Jan 27, 2025

AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease

Read More Dec 10, 2024

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

Read More Sep 27, 2024

AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase

Read More
All News